PPARG and obesity due to melanocortin 4 receptor deficiency: Peroxisome proliferator-activated receptor gamma (PPARγ) agonists improve adipogenesis and insulin resistance, as well as dyslipidemia, without reducing food intake, and mutations in the PPARγ are associated with obesity-related phenotypes.